Simone Giertz came to fame in the 2010s by becoming the self-proclaimed “queen of shitty robots.” On YouTube she demonstrated a hilarious series of self-built mechanized devices that worked perfectly for ridiculous applications, such as a headboard-mounted alarm clock with a rubber hand to slap the user awake.

But Giertz has parlayed her Internet renown into Yetch, a design company that makes commercial consumer products. (The company name comes from how Giertz’s Swedish name is properly pronounced.) Her first release, a daily habit-tracking calendar, was picked up by prestigious outlets such as the Museum of Modern Art design store in New York City. She has continued to make commercial products since, as well as one-off strange inventions for her online audience.

Where did the motivation for your useless robots come from?

Simone Giertz: I just thought that robots that failed were really funny. It was also a way for me to get out of creating from a place of performance anxiety and perfection. Because if you set out to do something that fails, that gives you a lot of creative freedom.

You built up a big online following. A lot of people would be happy with that level of success. But you moved into inventing commercial products. Why?

Giertz: I like torturing myself, I guess! I’d been creating things for YouTube and for social media for a long time. I wanted to try something new and also find longevity in my career. I’m not super motivated to constantly try to get people to give me attention. That doesn’t feel like a very good value to strive for. So I was like, “Okay, what do I want to do for the rest of my career?” And developing products is something that I’ve always been really, really interested in. And yeah, it is tough, but I’m so happy to be doing it. I’m enjoying it thoroughly, as much as there’s a lot of face-palm moments.

Giertz’s every day goal calendar was picked up by the Museum of Modern Art’s design store. Yetch

What role does failure play in your invention process?

Giertz: I think it’s inevitable. Before, obviously, I wanted something that failed in the most unexpected or fun way possible. And now when I’m developing products, it’s still a part of it. You make so many different versions of something and each one fails because of something. But then, hopefully, what happens is that you get smaller and smaller failures. Product development feels like you’re going in circles, but you’re actually going in a spiral because the circles are taking you somewhere.

What advice do you have for aspiring inventors?

Giertz: Make things that you want. A lot of people make things that they think that other people want, but the main target audience, at least for myself, is me. I trust that if I find something interesting, there are probably other people who do too. And then just find good people to work with and collaborate with. There is no such thing as the lonely genius, I think. I’ve worked with a lot of different people and some people made me really nervous and anxious. And some people, it just went easy and we had a great time. You’re just like, “Oh, what if we do this? What if we do this?” Find those people.

This article appears in the November 2024 print issue as “The Queen of Useless Robots.”

Scientists say geoengineering, or doing things like intentionally increasing Earth’s reflectivity or blocking the sun, is a “really big deal” in slowing down climate change. Here are the ideas they are proposing.

House Speaker Mike Johnson is seeking a smooth re-election to another term wielding the gavel, but a small group of discontent conservatives are again vying to shake things up at the top.

A new species of Jurassic dinosaur related to Tyrannosaurus rex has been discovered by paleontologists in Kyrgyzstan in Central Asia.

And the Epic Games Achievements system will start to roll out next week.

A chemical produced by gut bacteria could be the basis for a non-invasive test for endometriosis – and mouse experiments suggest it might also help treat the condition

Most ingredients touted as the key to better health fail to live up to the hype but fibre bucks this trend, with benefits for the whole body, not just the gut

Jessica Simpson sparked rumors this week with a cryptic post about making new music and having put up with "everything I did not deserve."

In this upcoming webinar, explore how to leverage the state-of-the-art high-frequency simulation capabilities of Ansys HFSS to innovate and develop advanced multiband antenna systems.

Overview

This webinar will explore how to leverage the state-of-the-art high-frequency simulation capabilities of Ansys HFSS to innovate and develop advanced multiband antenna systems. Attendees will learn how to optimize antenna performance and analyze installed performance within wireless networks. The session will also demonstrate how this approach enables users to extract valuable wireless and network KPIs, providing a comprehensive toolset for enhancing antenna design, optimizing multiband communication, and improving overall network performance. Join us to discover how Ansys HFSS can transform wireless system design and network efficiency approach.

What Attendees will Learn

• How to design interleaved multiband antenna systems using the latest capabilities in HFSS
• How to extract Network Key Performance Indicators
• How to run and extract RF Channels for the dynamic environment

Who Should Attend

This webinar is valuable to anyone involved in antenna, R&D, product design, and wireless networks.

Register now for this free webinar!

Kelly Clarkson filled in for Cowell as he recuperates from back surgery.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

While initial rumors suggested that Kinberg’s trilogy might continue the iconic Skywalker Saga, insiders have clarified that the upcoming series will chart new territory within the ‘Star Wars’ universe

Ajai Kesavan’s The Odd Couple attempts to bring laughter and nostalgia to Bengaluru with a fresh take on Neil Simon’s beloved comedy about unlikely roommates

Following yesterday’s big Disney Dreamlight Valley update on Apple Arcade and other platforms, a few more notable games on Apple’s …

Continue reading "Apple Arcade Weekly Round-Up: New Content and Feature Updates Are Now Live for TMNT Splintered Fate, Temple Run: Legends, Vampire Survivors, Simon’s Cat, and More"

But publisher leaves lucrative loophole for "early access" Patreon subscriptions.

The sound of silence, no more: Paul Simon and Art Garfunkel, who as folk duo Simon & Garfunkel were one of the most popular American musical acts of the 20th century, recently reunited after years without speaking.

Oversimplification about integration of traditional and modern treatment systems often creates confusion among the stakeholders, and nobody understands the reality of the integration and what it is meant for, said Dr.

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you:

• Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble

• Optum Rx joins the private label biosimilar bandwagon

• Biosimilars boom for provider-administered drugs

• Fresh evidence of how copay accumulators hurt patients

Plus, words of wisdom from Cencora's soon-to-be-former CEO Steve Collis.

P.S. Join my more than 58,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community.

There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

Read more »

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). The FTC rightly calls out how the gross-to-net bubble can raise patients’ out-of-pocket costs, while also acknowledging how rebates can reduce a plan's (but not the patient’s) costs. Apparently, the FTC believes that PBMs’ customers are pretty dumb, because PBMs are able to prevent plans from “appreciating” such healthcare financing dynamics.

Section V.E. of the complaint (starting on page 23) focuses on the PBMs’ alleged unlawful conduct related to preferring high-list/high-rebate insulin products over versions with lower list prices. I thought it would therefore be fun to take the Wayback Machine to November 2021, when I wrote about this specific topic.

Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. Much of the FTC’s description of the drug channel aligns with my commentary. But before you fist pump too hard for Ms. Khan’s FTC, you should pause to reflect on the agency’s legal theories in light of plans’ revealed preferences.

---

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release.

Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough.

Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Express Scripts will block both the branded reference product and the lower-priced, unbranded—but also interchangeable—version. Meanwhile, Prime Therapeutics will place both versions on its formularies, leaving the choice up to its plan sponsor clients.

Consequently, many commercial payers will adopt the more expensive product instead of the identical—but cheaper—version. As usual, patients will be the ultimate victims of our current drug pricing system.

Below, I explain the weird economics behind this decision, highlight the negative impact on patients, and speculate on what this all could mean for biosimilars’ future. Until plan sponsors break their addiction to rebates, today’s U.S. drug channel problems will remain.
Read more »

Here on Drug Channels, we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall.

Novel transparency information reveals that this good news doesn’t always translate into savings. Below, we rely on a unique data set from Turquoise Health to examine how much four national commercial health plans—Aetna, Anthem, Cigna, and UnitedHealthcare—paid hospitals for Avastin and its two most significant biosimilar competitors.

As we demonstrate, health plans pay hospitals far above acquisition costs for biosimilars. What’s more, plans can pay hospitals more for a biosimilar than for the higher-cost reference product. The U.S. drug channel system is warping hospitals’ incentives to adopt biosimilars, while simultaneously raising costs for commercial plans.

The namesake of my alma mater once said: “Sunlight is said to be the best of disinfectants.” What would happen if we disinfected the entire channel?
Read more »

The U.S. Food and Drug Administration posted a video:

¿Qué son los biosimilares? Los biosimilares son un tipo de medicamento que se usa para tratar una variedad de afecciones, como enfermedades crónicas de la piel y los intestinos, artritis, diabetes, afecciones renales, degeneración macular y algunos tipos de cáncer. Un biosimilar es un tipo de medicamento biológico. La mayoría de los medicamentos biológicos se elaboran usando fuentes vivas, como células animales, bacterias o levaduras. Debido a que en su mayoría provienen de fuentes vivas, todos los tipos de productos biológicos tienen diferencias menores que ocurren naturalmente entre los lotes de producción. Así como los medicamentos de marca tienen versiones genéricas, los biológicos originales pueden tener biosimilares. La cuidadosa revisión de datos, estudios y pruebas por parte de la FDA ayuda a garantizar que los productos biosimilares brinden los mismos beneficios de tratamiento que el producto biológico original aprobado por la FDA. Los biosimilares pueden brindarle más acceso a tratamientos importantes y también pueden ahorrarle dinero, dependiendo de su cobertura de seguro. Se han aprobado muchos biosimilares diferentes y se esperan aún más. Para obtener más información, visite www.fda.gov/biosimilars

<p>On 19&nbsp;September 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)&nbsp;adopted a positive opinion,&nbsp;recommending the granting of marketing authorization&nbsp;for&nbsp;two aflibercept biosimilars:&nbsp;&nbsp;Sandoz’s Afqlir and Samsung Bioepis’s Opuviz.&nbsp;These products are biosimilars of the reference product Eylea, developed by Regeneron and Bayer.</p>

<p>The US Food and Drug Administration (FDA) granted approval for two&nbsp;biosimilars, Formycon’s FYB202/Otulfi (ustekinumab-aauz) and Samsung Bioepis’ Soliris biosimilar, Epysqli (eculizumab-aagh), on 27 September and 22 July 2024, respectively. FYB202/Otulfi, a biosimilar referencing&nbsp;Johnson &amp; Johnson’s Stelara, while Epysqli is a biosimilar referencing Alexion’s Soliris.</p>

<p> <b>BIOSIMILAR RED TAPE ELIMINATION ACT (S2305):</b><br /> <b><i>Weakening FDA Regulatory Standards for Biosimilars, Undermining Physician Confidence and Jeopardizing Patient Health</i></b><br /><b>31 October 2024&nbsp;|&nbsp;</b><b><a href="https://youtu.be/X6-dYZ7fjhM" target="_blank">WATCH REPLAY</a></b></p>

<p>In October 2024, China based Bio-Thera Solutions&nbsp;(Bio-Thera)&nbsp;and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to&nbsp;Johnson &amp; Johnson’s Stelara (ustekinumab).</p>

<p>The European Commission (EC) granted marketing authorization for<b>&nbsp;</b>three ustekinumab biosimilars<b>:&nbsp;</b>Samsung Bioepis’ Eksunbi on 12 September 2024; Formycon’s Fymskina, and Fresenius Kabi’s&nbsp;Otulfi on 25 September 2024.</p>

<p> <b>Abstract</b><br />CinnaGen, the largest biopharmaceutical company in the MENA region, is a leader in developing follow-on biologicals/biosimilars. Dr&nbsp;Haleh Hamedifar, Chairperson of CinnaGen, spoke to GaBI<i>&nbsp;</i>(Generics and Biosimilars Initiative) about the company’s strategic focus, which includes expanding its product portfolio, entering highly regulated global markets, and advancing affordable treatments for conditions such as multiple sclerosis and&nbsp;immunological diseases—transforming healthcare in underserved regions.</p><p><b>Keywords</b>: Biosimilars, clinical development, commercialization, MENA</p>

By Ankit Mahadevia, chairman of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC A common theme in startup literature is that by cutting a range of unnecessary tasks, a step-change in results will follow.  I’ve found

The post Keeping It Simple: What Really Matters For Emerging Enterprises   appeared first on LifeSciVC.

This paper begins with a look at both optimization modeling and discrete-event simulation modeling, and explores how they can most effectively work together to create additional analytic value. It then considers two examples of a combined optimization and simulation approach and discusses the resulting benefits.

Life can sometimes feel like a never-ending cycle of stress and decisions. That's usually my weekdays in a nutshell: chasing deadlines, making tough calls, and hopping between meetings. When your brain feels like it's on overdrive, it's time to hit pause. Engaging in some therapeutic activities can give your mind the breather it desperately needs. The good news? They don't have to be complicated or time-consuming. Here are some that can work wonders for your mental clarity and overall well-being. Step outside for a walk Walking is one of the simplest ways to clear your mind. It's amazing what a little fresh air at your nearby PCN can do. Just stepping outside and getting those legs moving can shift your perspective in a matter of minutes — and burn a few calories too! Disconnect from your phone and enjoy the sights and sounds of the great outdoors. I find that a 30-min walk and a change of environment works wonders for me, helping me rationally dissect my worries, such as my crushing feelings of inadequacy at work.

The �Design Smart, Live Beautifully� Home Tour coincides with the launch of the 2014 model of Blu�s award-winning�Breezehouse, which is�packed with luxurious features and an even more spacious floor plan

Blu Homes Breezehouse is the Real Simple and This Old House "2014 Dream Home of the Year."

Elliott Vichinsky, MD, University of California, San Francisco (UCSF) Benioff Children's Hospital Oakland

Simple steps for Alzheimer's planning.

Are you aware of a SimCity 2000 release that came on A LOT OF FLOPPIES? As in, ten or more 3.5" disks? Because I spent the better part of an afternoon watching my friend install it in the mid 90s. Yet there's no record that this version of the game existed.

The US Census Bureau processes data before publishing it in order to keep personal information private – but a new approach could maintain the same privacy while improving accuracy

Schools are struggling to cope with the logistical hurdles and cost required to make the adjustments.

Ellie Simmonds becomes the first person to break a world record at London's Aquatics Centre in the 200m individual medley.

Double Paralympic champion Eleanor Simmonds says she would not support any plan to combine the Olympic and Paralympic Games.

medlinkZika virus/medlink (mosquito-borne disease) that infected five people in Maharashtra's Pune was found to be asymptomatic and resembles medlinkdengue fever/medlink, said health experts.

Highlights: A 15-minute daily exercise challenge led to a 12-minute increase in daily physical activity among parti

Highlights: Hibiscus tea is packed with antioxidants and vitamins Supports heart health and aids digestion Ma

Highlights: Balance testing shows links between stability, strength, and aging Age-related muscle and sensory c

New test that can detect which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin has been discovered. In

Optineurin, or OPTN protein when present in the cells it restricts the spread of HSV-1, the herpes simplex virus type 1. The study finds a potential direct

Children born through frozen embryo transfer have metabolic profiles similar to those born through fresh embryo transfer, according to a study published

medlinkAmyotrophic lateral sclerosis/medlink (ALS) is a medlinkneurodegenerative disease/medlink that affects neurons in the brain and spinal cord.

A simple 30-second balance test on one leg may reveal key indicators of aging and overall health. Testing balance reflects strength, stability, and fall risk.